Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company, today announced that its CEO, Natalia Perekhvatova, is invited to present during the 7th Annual LSX World Congress 2021. The Congress will take place on Feb 1-5, 2021.
“We look forward to LSX Word Congress and to the opportunity for Mitotech to highlight its recent clinical developments in ophthalmology,” said Natalia Perekhvatova.
About Mitotech S.A.
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. In VISTA-1 – a Phase 2b/3 clinical study in the United States (NCT03764735) - SkQ1 showed evidence of efficacy in reducing both the signs and symptoms in Dry Eye subjects. Topline data from Mitotech's Phase 3 pivotal study (VISTA-2) is expected in the first quarter of 2021. Dry AMD and LHON programs for SkQ1 ophthalmic solution are at pre-Phase 2 stage with Phase 2 studies projected to start in 2021.